Peter Nash
Tweet
Grappa Symposium: Leung Obesity in PsA - done deal
@RheumNow #APLAR2026 https://t.co/3YQT4kiPer
Recent News
Read ArticleDr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
Peter Nash
Tweet
AxSpA+rash vs Axial PsA Kishimoto : two phenotypes of the same disease and to maximise specificity Axis study - imaging criteria = AxSpA phenotype
@RheumNow #APLAR2026 https://t.co/UYFnA3AyUM
sheila
Tweet
An important and relevant reminder from @rheumarhyme on AI use
@RheumNow #APLAR2026 https://t.co/7Ratb6aQOD
sheila
Tweet
AI can be helpful in manuscript creation
As the author:
> always verify the draft - allow time to check
> take full responsibility of the content - review and revise the final manuscript
@RheumNow #APLAR2026 https://t.co/cQsEtDc7z1
Jiha Lee
Tweet
Case quiz: 38F fever, tetraparesis, hallucinations, slurred speech. Low C3, ANA 1:100, WBC 26,320, normal CSF/Ca/PTH. CT: basal ganglia calcification. Dx?
Answer: SLE with Fahr syndrome (focal NPSLE) plus urosepsis. Keep infection in rheum Ddx. P#325 #APLAR26 @RheumNow https://t.co/Gsb8dquwHL
sheila
Tweet
Dr. Poddubny on AI & machine learning in SpA
AI has enabled the analysis of large data sets offering a support for clinical decision-making.
Future directions? Making scans faster leading to rapid analysis
Challenge: access to large, high quality data
@RheumNow #APLAR2026 https://t.co/UhdjSRXtOv
Jiha Lee
Tweet
Better drugs only help if patients can get them. In an APLAR PsA registry, 43% of lowest-GDP patients had not reached MDA and were not on a biologic or targeted DMARD. Coverage, reimbursement and social support needed, not just science. P#242 #APLAR26 @RheumNow https://t.co/Rms4QsbcII
Jiha Lee
Tweet
Raychaudhuri (day 2 plenary): Reconceptualizing cells as continuous states, not discrete types. In RA synovium, AMP defined six inflammation patterns (CTAPs) with key cell states, e.g. Tph in T+B. Do CTAPs respond to different targets? #APLAR26 @RheumNow https://t.co/jIosTqv5qZ
Dr. John Cush
Tweet
FDA has approved the IL-23 inhibitor tildrakizumab (Ilumya) use in adults with active psoriatic arthritis (PsA), expanding the interleukin indications beyond moderate-to-severe plaque psoriasis. (Based on INSPIRE-1/2; >800 adults, 52-week RCTs) https://t.co/tCKZQwf74A https://t.co/Qffr1ZAMd7
Dr. John Cush
Tweet
Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top?
The treatment of active TAK is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage.
https://t.co/J1EQHGzR5O https://t.co/i59kRGJCoK
Dr. John Cush
Tweet
Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 https://t.co/JCTszYa57m
Dr. John Cush
Tweet
JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/xTlr5lrwUz
Dr. John Cush
Tweet
"We really need to ask every patient who has psoriasis about their joints” – Dr. Ahmad Amin, Dermatologist
Watch Dr. Amin and Dr. Saakshi Khattri discuss the link between skin and joints in PsA. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/rp2e5oknVF https://t.co/nf2vpvNJuV
sheila
Tweet
Prof. Mease shares this important slide illustrating how excessive adipose tissue contributes to PsA dev’t 👇
Dysfunctional adipose tissue enables overall amplification of inflammation in obese pts with PsA
@RheumNow #APLAR2026 https://t.co/1YtcqxM4B3
sheila
Tweet
Optimizing GC use in SLE:
In arthritis, avoid oral GC - consider NSAIDS, csDMARDs, small molecules or biologics
On GC initiation, hit hard w/pulse MP then taper early and rapidly
In LN, treat aggressively bec damage is driven by dse activity, not meds
@RheumNow #APLAR2026 https://t.co/Q5gFpr8P9k
Jiha Lee
Tweet
OA injections span three tiers: symptom-modifying (steroid, HA, polynucleotides), structure-oriented (sprifermin, Wnt inhibitors) and biologic (PRP, MSCs, EVs). None looks far superior to steroid or HA for symptoms; structural benefit is the goal. OA SIG #APLAR26 @RheumNow https://t.co/4R6Oxd0BvL
Jiha Lee
Tweet
The @RheumNow crew together at #APLAR2026 https://t.co/9YizHIFprF
Peter Nash
Tweet
T cell clone in AxSpA Trvb9 & Trav 21 B27 pos pts - t cell engager developed
@RheumNow #APLAR2026 https://t.co/Jt7XBu3Kok
Dr. John Cush
Tweet
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic https://t.co/TPqPKP5MRl
Video
Podcasts
DERM on RheumNow PODCAST (October 2026)
Mixed Drinks, Mixed Results (10.30.2026)
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings-
Double Trouble (10.23.2026)
Therapeutic Updates
PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Saakshi Khattri hosts dermatologist Dr. Ahmad Amin and gastroenterologist Dr. Joshua Steinberg to discuss multidisciplinary care in PsA and other immune-mediated inflammatory diseases. Learn how signals in the skin and gut may prompt the need for collaboration across specialties to support better patient outcomes that extend beyond the joints.
Read Post
Obesity – Inflammation – PsA
Sponsored by Lilly Medical Affairs
Learn about the inflammatory intersection between Psoriatic Arthritis and Obesity, and why adiposity is more than a comorbidity.
Read Post
Clinical dilemmas in axSpA and PsA
Sponsored by UCB
Explore some of the challenges rheumatologists face in clinical practice, including expert perspectives from UCB's Annual International Immunology Summit.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
